EC approves Zejula as first-line monotherapy maintenance treatment in advanced ovarian cancer

This article was originally published here

This approval makes Zejula the only PARP inhibitor approved in the European Union for use as a monotherapy for patients with advanced ovarian cancer, regardless of their biomarker

The post EC approves Zejula as first-line monotherapy maintenance treatment in advanced ovarian cancer appeared first on Pharmaceutical Business review.